Pacific Biosciences of California Inc. (NASDAQ:PACB) went up by 7.23% from its latest closing price compared to the recent 1-year high of $53.69. The company’s stock price has collected -1.58% of loss in the last five trading sessions. Press Release reported 16 hours ago that Pacific Biosciences and Invitae Announce Intent to Expand Collaboration
Is It Worth Investing in Pacific Biosciences of California Inc. (NASDAQ :PACB) Right Now?
Plus, the 36-month beta value for PACB is at 1.08. Opinions of the stock are interesting as 3 analysts out of 5 who provided ratings for Pacific Biosciences of California Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $47.40. PACB currently public float of 184.89M and currently shorts hold a 7.39% ratio of that float. Today, the average trading volume of PACB was 2.42M shares.
PACB’s Market Performance
PACB stocks went down by -1.58% for the week, with a monthly jump of 0.17% and a quarterly performance of 0.34%, while its annual performance rate touched 592.76%. The volatility ratio for the week stands at 9.15% while the volatility levels for the past 30 days are set at 6.32% for Pacific Biosciences of California Inc.. The simple moving average for the period of the last 20 days is -7.33% for PACB stocks with a simple moving average of 7.73% for the last 200 days.
Analysts’ Opinion of PACB
Many brokerage firms have already submitted their reports for PACB stocks, with Piper Sandler repeating the rating for PACB by listing it as a “Overweight.” The predicted price for PACB in the upcoming period, according to Piper Sandler is $52 based on the research report published on February 11th of the current year 2021.
Piper Sandler, on the other hand, stated in their research note that they expect to see PACB reach a price target of $12. The rating they have provided for PACB stocks is “Neutral” according to the report published on November 03rd, 2020.
JP Morgan gave a rating of “Overweight” to PACB, setting the target price at $15 in the report published on October 02nd of the previous year.
PACB Trading at 2.83% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.61% of loss for the given period.
Volatility was left at 6.32%, however, over the last 30 days, the volatility rate increased by 9.15%, as shares sank -1.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.32% upper at present.
During the last 5 trading sessions, PACB fell by -1.58%, which changed the moving average for the period of 200-days by +178.10% in comparison to the 20-day moving average, which settled at $31.48. In addition, Pacific Biosciences of California Inc. saw 12.57% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at PACB starting from Ericson William W., who sale 37,500 shares at the price of $25.89 back on May 25. After this action, Ericson William W. now owns 0 shares of Pacific Biosciences of California Inc., valued at $971,058 using the latest closing price.
Hunkapiller Michael, the Director of Pacific Biosciences of California Inc., sale 234,246 shares at $31.02 during a trade that took place back on Feb 26, which means that Hunkapiller Michael is holding 848,405 shares at $7,265,866 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -132.31 for the present operating margin
- +41.28 for the gross margin
The net margin for Pacific Biosciences of California Inc. stands at +37.27. The total capital return value is set at -42.25, while invested capital returns managed to touch 12.51. Equity return is now at value -30.10, with -10.90 for asset returns.
Based on Pacific Biosciences of California Inc. (PACB), the company’s capital structure generated 12.52 points at debt to equity in total, while total debt to capital is 11.13. Total debt to assets is 10.15, with long-term debt to equity ratio resting at 11.23. Finally, the long-term debt to capital ratio is 9.98.
When we switch over and look at the enterprise to sales, we see a ratio of 54.01, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 4.91 and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.24.